TA-8995: all 27 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's DiseaseRecruitingNCT07794670Phase 2
• Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy VolunteersRecruitingNCT06982508Phase 2
• Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) LevelsRecruitingNCT06496243Phase 2
• Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying TherapiesCompletedNCT06005597Phase 3Results posted
• Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.CompletedNCT05425745Phase 3Results posted
• A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.CompletedNCT05421078Phase 2Results posted
• Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS TherapyCompletedNCT05266586Phase 2Results posted
• Proof-of-concept, Open-label Study in Patients With Early Alzheimer's DiseaseCompletedNCT05161715Phase 2Results posted
• Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesCompletedNCT05142722Phase 3Results posted
• Randomized Study of Obicetrapib in Combination With EzetimibeCompletedNCT04770389Phase 2Results posted
• Randomized Study of Obicetrapib as an Adjunct to Statin TherapyCompletedNCT04753606Phase 2Results posted
• A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic SyndromeActive, not recruitingNCT07219602Phase 3
• A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult SubjectsCompletedNCT06547359Phase 1
• A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary PlaqueActive, not recruitingNCT06305559Phase 3
• Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without ObicetrapibCompletedNCT06250205Phase 1
• A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and RosuvastatinCompletedNCT06081166Phase 1
• PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic FunctionCompletedNCT06048302Phase 1
• Investigating the Effect of Obicetrapib on Lipoprotein MetabolismActive, not recruitingNCT05972278Phase 1
• Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseaseActive, not recruitingNCT05202509Phase 3
• Bioequivalence Study of Capsule and Tablet Formulations of TA-8995CompletedNCT02523391Phase 1
• ADME Study in Healthy Male Subjects With TA-8995CompletedNCT02408055Phase 1
• A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)CompletedNCT02241772Phase 1/2
• Study of the Electrocardiographic Effects of TA-8995CompletedNCT02241759Phase 1
• A Preliminary Drug Drug Interaction Study With TA-8995CompletedNCT02124954Phase 1
• TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)CompletedNCT01970215Phase 2
• Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy SubjectsCompletedNCT01879020Phase 1
• Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy SubjectsCompletedNCT01878474Phase 1

← TA-8995 overview